Search results
Results from the WOW.Com Content Network
Parinaud's syndrome is a cluster of abnormalities of eye movement and pupil dysfunction, characterized by: Paralysis of upwards gaze: Downward gaze is usually preserved. This vertical palsy is supranuclear , so doll's head maneuver should elevate the eyes, but eventually all upward gaze mechanisms fail.
Frequently, paralysis of upward gaze along with several ocular findings such as convergence retraction nystagmus and eyelid retraction also known as Collier's sign and Light Near Dissociation (pupil accommodates but doesn't react to light) are known collectively as Parinaud's syndrome [1] or Dorsal Mid-brain syndrome, are the only physical ...
Parinaud's oculoglandular syndrome (POS) is a medical condition characterized by a specific set of symptoms affecting the eye and nearby lymph nodes. Named after the French ophthalmologist Henri Parinaud , it should not be confused with the neurological syndrome caused by a lesion in the midbrain which is also known as Parinaud's syndrome .
Parinaud's syndrome, which can mimic some aspects of spasm of the near reflex, such as excessive accommodation and convergence; however, pupillary near-light dissociation, not miosis, is a feature of Parinaud's syndrome. [8]
A third cause of light-near dissociation is Parinaud syndrome, also called dorsal midbrain syndrome. This uncommon syndrome involves vertical gaze palsy associated with pupils that “accommodate but do not react." [5] The causes of Parinaud syndrome include brain tumors (pinealomas), multiple sclerosis and brainstem infarction.
This can result in vision changes and Parinaud's syndrome. [3] Due to the aggressive nature of the disease, tumor spread at the time of diagnosis is common. [13] Pineoblastomas often invades locally, with spread to the head and spine seen in 25–41% of patients. [3] While CNS spread is relatively common, these tumors rarely cause distant ...
Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS). [23]
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. [ 2 ] [ 4 ] It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or ...